My research in prostate cancer has centered in two main areas (1) androgen receptor changes in the evolution of hormone refractory prostate cancer and (2) clinical trials of novel hormone therapy and chemotherapy with correlative molecular endpoints. The androgen receptor research has demonstrated that (1) androgen receptor point mutations occur in about 20-30% of hormone refractory metastases (2) androgen receptor mutations result in functional changes (3) the presense androgen receptor mutations correlates with response to second-line hormone therapies. Clinical trials of novel androgen receptor directed therapy such as abiraterone, enzalutamide and galeterone are ongoing. Other clinical trials include obtaining samples of metastatic prostate cancer for laboratory analysis to help understand mechanisms of response and resistance with the goal of developing more personalized therapies.
I am developing and testing a personalized patient web page for patients enrolled on clinical trials in which patient clinic visits will be videoed and uploaded to the site so that patients and family can "revisit the visit".